News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Jamil Asselah

Articles by Jamil Asselah

80 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Final Results From the Phase 1b/2 BEGONIA Study

ByPeter Schmid, MD,Hwei-Chung Wang,Filipa Lynce,Yeon Hee Park,Cynthia X. Ma, MD, PhD,Kyung Hae Jung,Shin-Cheh Chen,Ming-Feng Hou,Catherine Prady,Ling-Ming Tseng,Jamil Asselah,Piotr J. Wysocki,Simon Lord,Purnima Rao-Melacini,Ross Stewart,Karola Warzyszyńska,Petra Vuković,Seock-Ah Im

June 8th 2026

Dato-DXd plus durvalumab demonstrated robust antitumor activity as first-line treatment for advanced/metastatic triple-negative breast cancer in the phase 1b/2 BEGONIA study, with manageable safety.

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

ByJamil Asselah,Cynthia X. Ma, MD, PhD,Zbigniew Nowecki,Robert Huisden,Ross Stewart,Petra Vuković,Peter Schmid, MD

April 28th 2023

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer

NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing

Zanzalintinib/Atezolizumab Misses Survival End Point in Non-MSI-H mCRC Subgroup

Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial

Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview